Medulloblastoma Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

DelveInsight's, "Medulloblastoma Pipeline Insight" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Medulloblastoma pipeline landscape. It covers the Medulloblastoma pipeline drug profiles, including Medulloblastoma clinical trials and nonclinical stage products. It also covers the Medulloblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Medulloblastoma Emerging drugs, the Medulloblastoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Medulloblastoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Medulloblastoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Medulloblastoma clinical trials studies, Medulloblastoma NDA approvals (if any), and product development activities comprising the technology, Medulloblastoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Click here to know more about the Medulloblastoma Pipeline Outlook- https://www.delveinsight.com/report-store/medulloblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key takeaways from the Medulloblastoma Pipeline Report
• Over 15+ Medulloblastoma companies are evaluating 15+ Medulloblastoma pipeline therapies in various stages of development, and their anticipated acceptance in the Medulloblastoma market would significantly increase market revenue.
• The leading Medulloblastoma Companies includes Bayer, Novartis, Celgene, Y-mAbs Therapeutics, Apices Soluciones S.L., Bristol-Myers Squibb, Oncurious NV, Eli Lilly and Company, Valent technologies, Guangdong Zhongsheng Pharmaceutical, Chimerix, Kintara Therapeutics, Curtana Pharmaceuticals, VBI Vaccines, Nurix, Oncoheroes Biosciences, Midatech, and others.
• Promising Medulloblastoma Pipeline Therapies includes LDE225, TMZ, Nifurtimox, Cyclophosphamide, Topotecan, TPI 287, Irinotecan, and others.
• The Medulloblastoma companies and academics are working to assess challenges and seek opportunities that could influence Medulloblastoma R&D. The Medulloblastoma pipeline therapies under development are focused on novel approaches to treat/improve Medulloblastoma.
• In March 2025, Novartis announced a Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
• In November 2024, Valent Technologies, LLC announced a Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors

To explore more information on the latest breakthroughs in the Medulloblastoma Pipeline treatment landscape of the report, click here @ Medulloblastoma Pipeline Outlook- https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Medulloblastoma Overview
Medulloblastoma is a malignant brain tumor that primarily affects children, though it can also occur in adults. Originating in the cerebellum, it is the most common type of pediatric brain cancer, accounting for about 20% of childhood brain tumors. Medulloblastoma typically presents with symptoms such as headaches, nausea, vomiting, and difficulties with balance and coordination due to its location in the brainstem and cerebellum.
Medulloblastoma is classified into different molecular subgroups, each with distinct genetic and clinical characteristics, influencing prognosis and treatment strategies. These subgroups include WNT, SHH, Group 3, and Group 4, which are identified based on genetic mutations and expression profiles. Advances in molecular biology have significantly improved the understanding of medulloblastoma, leading to the development of targeted therapies aimed at specific genetic alterations.
Treatment for medulloblastoma typically involves a combination of surgery, radiation therapy, and chemotherapy, with the goal of removing the tumor and preventing recurrence. While survival rates have improved due to these treatments, they are associated with long-term side effects, especially in pediatric patients. Ongoing research into novel therapies, including immunotherapy and targeted treatments, is providing hope for more effective and less toxic options for medulloblastoma management.

For further information, refer to the detailed Medulloblastoma Unmet Needs, Medulloblastoma Market Drivers, and Medulloblastoma Market Barriers, click here for Medulloblastoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Medulloblastoma Emerging Drugs Profile
Pomalidomide - Bristol-Myers Squibb
Pomalidomide is an investigational drug candidate being developed by Bristol-Myers Squibb for the treatment of medulloblastoma. This novel therapeutic was previously explored for multiple indications, including metastatic adenocarcinoma of the pancreas, soft tissue sarcoma, metastatic hormone-refractory prostate cancer, systemic sclerosis (scleroderma), chronic cough, and small-cell lung cancer. Additionally, it had been under development for acute myelocytic leukemia, primary myelofibrosis (chronic idiopathic myelofibrosis), and post-essential thrombocythemia myelofibrosis. Currently, Pomalidomide is in Phase II clinical trials for the treatment of medulloblastoma.

MTX110 - Biodexa Pharmaceuticals
MTX110 is an innovative water-soluble formulation of panobinostat free base, achieved through complexation with hydroxapropyl-β-cyclodextrin (HPBCD), enabling convection-enhanced delivery (CED) at potentially therapeutic doses directly to the tumor site. Panobinostat, a hydroxamic acid, functions as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation, panobinostat lactate (Farydak®), is unsuitable for brain cancer treatment due to poor blood-brain barrier penetration and inadequate drug concentrations in the brain.
Based on promising translational science data, MTX110 is being clinically evaluated for diffuse intrinsic pontine glioma (DIPG) and recurrent medulloblastoma and is also undergoing preclinical evaluation for glioblastoma. The drug is administered directly into and around the patient's tumor via a catheter system (e.g., CED or fourth ventricle infusions) to bypass the blood-brain barrier. This localized delivery maximizes drug exposure to the tumor while minimizing systemic toxicity and associated side effects. Panobinostat has demonstrated high potency against DIPG tumor cells in both in vitro and in vivo models, ranking as the most promising agent among 83 anticancer drugs tested across 14 patient-derived DIPG cell lines. Currently, MTX110 is in Phase I clinical development for the treatment of medulloblastoma.

Silmitasertib (CX-4945): Senhwa Biosciences
Silmitasertib (CX-4945), an oral small molecule inhibitor of casein kinase 2 (CK2). It caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells. The drug is in Phase I/II clinical development for the treatment of Medulloblastoma. Silmitasertib is a first-in-class small molecule drug that targets Casein Kinase 2 (CK2), a protein involved in the DNA repair mechanism of cancer cells.

Medulloblastoma Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Medulloblastoma. The companies which have their Medulloblastoma drug candidates in the most advanced stage, i.e. Phase II include, Y-mAbs Therapeutics.

Request a sample and discover the recent advances in Medulloblastoma Ongoing Clinical Trial Analysis and Medications, click here @ Medulloblastoma Treatment Landscape- https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Medulloblastoma Pipeline Report
• Coverage- Global
• Medulloblastoma Companies- Bayer (ETR: BAYN), Novartis (SWX: NOVN), Celgene (NYSE: CELG), Y-mAbs Therapeutics (NASDAQ: YMAB), Apices Soluciones S.L., Bristol-Myers Squibb (NYSE: BMY), Oncurious NV, Eli Lilly and Company (NYSE: LLY), Valent Technologies, Guangdong Zhongsheng Pharmaceutical (SZSE: 002317), Chimerix (NASDAQ: CMRX), Kintara Therapeutics (NASDAQ: KTRA), Curtana Pharmaceuticals, VBI Vaccines (NASDAQ: VBIV), Nurix (NASDAQ: NRIX), Oncoheroes Biosciences, Midatech (AIM: MTPH)., and others.
• Medulloblastoma Pipeline Therapies- LDE225, TMZ, Nifurtimox, Cyclophosphamide, Topotecan, TPI 287, Irinotecan, and others.
• Medulloblastoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Medulloblastoma Market Drivers and Medulloblastoma Market Barriers, click here @ Medulloblastoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Medulloblastoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mid Stage Products (Phase II)
7. Drug Name: Company Name
8. Drug profiles in the detailed report.....
9. Early Stage Products (Phase I/II)
10. 177Lu-omburtamab-DTPA: Y-mAbs Therapeutics
11. Drug profiles in the detailed report.....
12. Preclinical stage products
13. CT 179: Curtana Pharmaceuticals
14. Drug profiles in the detailed report.....
15. Inactive Products
16. Medulloblastoma Key Companies
17. Medulloblastoma Key Products
18. Medulloblastoma- Unmet Needs
19. Medulloblastoma- Market Drivers and Barriers
20. Medulloblastoma- Future Perspectives and Conclusion
21. Medulloblastoma Analyst Views
22. Medulloblastoma Key Companies
23. Appendix

Got Queries? Find out the related information on Medulloblastoma Mergers and acquisitions, Medulloblastoma Licensing Activities @ Medulloblastoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.